Skip to main content

Table 6 Factors associated with vaccination coverage*

From: Influenza and pneumococcal vaccination coverage in Latin American patients with systemic lupus erythematosus: a cross-sectional and comparative study

 

Influenza coverage

Pneumococcal coverage

Initial analysis

Adjusted model a

Initial analysis

Adjusted model a

OR (95% CI)

p value

OR (95% CI)

p value

OR (95% CI)

p value

OR (95% CI)

p value

Latin America

 Chronic renal disease

1.30 (0.96–1.77)

0.089

1.38 (1.01–1.88)

0.044

2.00 (1.44–2.77)

< 0.001

2.30 (1.63–3.35)

< 0.001

 Age > 50 years

1.69 (1.22–2.35)

0.001

1.70 (1.22–2.37)

0.002

1.63 (1.15–2.32)

0.006

1.67 (1.15–2.42)

0.007

 Tetanus coverage

2.24 (1.75–2.86)

< 0.001

2.25 (1.75–2.88)

< 0.001

3.62 (2.74–4.80)

< 0.001

3.79 (2.85–5.05)

< 0.001

Europe

 Chronic respiratory disease

NS d

NS d

  

1.73 (1.18–2.56)

0.006

1.86 (1.23–2.82)

< 0.001

 Smoking b

0.57 (0.42–0.79)

0.001

0.55 (0.39–0.76)

< 0.001

0.72 (0.52–1.01)

0.058

0.67 (0.47–0.96)

0.029

 Immunosuppressors c

1.77 (1.27–2.47)

0.001

1.97 (1.40–2.77)

< 0.001

1.71 (1.20–2.44)

0.003

1.85 (1.27–2. 70)

< 0.001

 Age > 50 years

2.16 (1.53–3.08)

< 0.001

2.37 (1.65–3.41)

< 0.001

NS d

NS d

  

 Tetanus coverage

1.45 (1.08–1.93)

0.012

1.54 (1.14–2.07)

0.005

3.74 (2.72–5.14)

< 0.001

3.91 (2.83–5.40)

< 0.001

  1. * Statistical significance was set at p value < 0.05
  2. aOnly variables that were significant in the univariate analysis (p < 0.10) were included
  3. bSmoking was defined as currently smoking or having quit < 6 months ago
  4. cNot including corticosteroids and hydroxychloroquine
  5. dNot significant